Diagnos Laboratorium Utama Past Earnings Performance
Past criteria checks 0/6
Diagnos Laboratorium Utama's earnings have been declining at an average annual rate of -39.3%, while the Healthcare industry saw earnings growing at 3.7% annually. Revenues have been declining at an average rate of 30.3% per year.
Key information
-39.3%
Earnings growth rate
-46.0%
EPS growth rate
| Healthcare Industry Growth | 14.1% |
| Revenue growth rate | -30.3% |
| Return on equity | -2.4% |
| Net Margin | -3.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Diagnos Laboratorium Utama makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 155,530 | -4,759 | 72,301 | 0 |
| 31 Mar 24 | 149,805 | -9,973 | 72,284 | 0 |
| 31 Dec 23 | 145,696 | -13,656 | 73,420 | 0 |
| 30 Sep 23 | 156,173 | -10,146 | 76,204 | 0 |
| 30 Jun 23 | 167,242 | -5,502 | 78,789 | 0 |
| 31 Mar 23 | 172,634 | 799 | 79,480 | 0 |
| 31 Dec 22 | 192,886 | 12,665 | 78,320 | 0 |
| 30 Sep 22 | 195,178 | 12,488 | 77,927 | 0 |
| 30 Jun 22 | 230,248 | 28,639 | 71,336 | 0 |
| 31 Mar 22 | 272,200 | 50,909 | 68,185 | 0 |
| 31 Dec 21 | 302,182 | 64,304 | 67,127 | 0 |
| 30 Sep 21 | 333,309 | 88,913 | 51,077 | 0 |
| 30 Jun 21 | 307,629 | 90,578 | 42,975 | 0 |
| 31 Mar 21 | 255,411 | 72,918 | 30,605 | 0 |
| 31 Dec 20 | 183,171 | 52,687 | 18,493 | 0 |
| 30 Sep 20 | 115,389 | 30,409 | 14,440 | 0 |
| 30 Jun 20 | 73,721 | 13,521 | 11,407 | 0 |
| 31 Mar 20 | 55,994 | 8,861 | 10,206 | 0 |
| 31 Dec 19 | 51,338 | 9,275 | 6,693 | 0 |
| 31 Dec 18 | 38,553 | 9,265 | 3,759 | 0 |
| 31 Dec 17 | 14,014 | 1,382 | 2,410 | 0 |
Quality Earnings: DGNS is currently unprofitable.
Growing Profit Margin: DGNS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DGNS is unprofitable, and losses have increased over the past 5 years at a rate of 39.3% per year.
Accelerating Growth: Unable to compare DGNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DGNS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (2.7%).
Return on Equity
High ROE: DGNS has a negative Return on Equity (-2.42%), as it is currently unprofitable.